The European healthcare landscape has more than a decade of in-market experience with supportive care biosimilars. However, we’re entering a new era for biosimilars in oncology with the recent launch of therapeutic biosimilars in the EU.
At the recent European Society for Medical Oncology (ESMO) Congress, held Sept. 8-12 in Madrid, the European medical industry came together for clinical data updates, expertise-sharing and advisory guidance. There were six presentations on biosimilars at the event, including those sponsored by biosimilar manufacturers. Consistent across many sessions were four core themes:Read More